Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of biotech firm Idenix Pharmaceuticals
So what: Bristol-Myers Squibb
Now what: Already in phase 2b FDA trials, IDX184 is Idenix's greatest hope for a future blockbuster at the moment. The oral drug is designed to enhance the efficiency of other medications, which is why the stock jumped on today's news -- Idenix doesn't have a big-name partner for the endgame yet and might end up arm-in-arm with J&J or Bristol-Myers. The firm is no stranger to big-name collaborations, having licensed hepatitis B medication Tyzeka to Novartis
Interested in more info about Idenix Pharmaceuticals? Click here to add it to My Watchlist.